PET/CT for Staging and Diagnosis of Lung Cancer
Positron emission tomography (PET) is an imaging technique, which allows for accurate non-invasive measurements of metabolic pathways in tissues of man in vivo. The most frequently used tracer in PET oncology is the glucose analog 18F-fluoro-2-deoxy-glucose (FDG). The preferential accumulation of FDG in neoplastic cells permits differentiation between benign and malignant tissue. The ability to perform whole-body imaging within one examination without increasing the radiation burden makes it an ideal technique to “screen” patients for cancer deposits. Also in thoracic oncology, FDG-PET has proven its superiority over other imaging techniques in staging nodal and metastatic disease. However, the poor anatomic detail of PET can lead to errors in diagnosis and staging. Through the integration of computer tomography (CT) and PET into one machine, form and function are merged to create a better imaging tool. In this chapter, we will highlight the recent developments in hybrid machinery (time-of-flight PET, PET-MR) and review the role of integrated PET/CT in the diagnosis and staging of lung cancer.
KeywordsPositron Emission Tomography Computer Tomography Positive Predictive Value Positron Emission Tomography Image Positron Emission Tomography Scanning
- Silvestri GA, Gould MK, Margolis ML et al (2007) Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines 132(Suppl 3):178S–201S (2nd ed)Google Scholar